Mereo BioPharma Group plc (MREO) has gained over 160% in the last three trading days as it gears up for a couple of important clinical trial catalysts in the coming year.
The Company's lead drug candidate is Setrusumab, a potential treatment for osteogenesis imperfecta, also known as brittle bone disease. Setrusumab was acquired from Novartis in 2015.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com